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Abstract
Background: Ivermectin is an excellent microfilaricide against Onchocerca volvulus. However, in some regions, long
term use of ivermectin has resulted in sub-optimal responses to the treatment. More data to properly document the
phenomenon in various contexts of ivermectin mass drug administration (IVM-MDA) is needed. Also, there is a need to
accurately monitor a possible repopulation of skin by microfilariae following treatment. Skin snip microscopy is known
to have a low sensitivity in individuals with light infections, which can be the case following treatment. This study was
designed with two complementary objectives: (i) to assess the susceptibility of O. volvulus microfilariae to ivermectin in
two areas undergoing IVM-MDA for different lengths of time, and (ii) to document the repopulation of skin by the O.
volvulus microfilariae following treatment, using 3 independent diagnostic techniques.
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Method: Identified microfilaridermic individuals were treated with ivermectin and re-examined after 1, 3, and 6months
using microscopy, actin real-time PCR (actin-qPCR) and O-150 LAMP assays. Susceptibility to ivermectin and trends in
detecting reappearance of skin microfilariae were determined using three techniques. Microscopy was used as an
imperfect gold standard to determine the performance of actin-qPCR and LAMP.
Results: In Bafia with over 20 years of IVM-MDA, 11/51 (21.6%) direct observe treated microfilaridemic participants were
still positive for skin microfilariae after 1 month. In Melong, with 10 years of IVM-MDA, 2/29 (6.9%) treated participants
were still positive. The microfilarial density reduction per skin biopsy within one month following treatment was
significantly lower in participants from Bafia.
In both study sites, the molecular techniques detected higher proportions of infected individuals than microscopy at all
monitoring time points. LAMP demonstrated the highest levels of sensitivity and real-time PCR was found to have the
highest specificity.
Conclusion: Patterns in skin mirofilariae clearance and repopulation were established. O. volvulus worms from Bafia
with higher number of annual MDA displayed a lower clearance and higher repopulation rate after treatment with
ivermectin. Molecular assays displayed higher sensitivity in monitoring O. volvulus microfilaridemia within six months
following treatment.
Keywords: Susceptibility, Monitoring, O. volvulus, Microfilaridemia, Microscopy, Real-time PCR, LAMP, Microfilaricides
Background
Onchocerciasis (river blindness) is a disease caused by
infection with the filarial nematode Onchocerca volvulus
and transmitted by female blackflies of the genus Simu-
lium. It is one of the neglected tropical diseases with an
estimated 21 million people infected, 99% of which are
in Africa [1]. Infection with the parasite is known to be
responsible for severe skin and ocular manifestations [2–
5]. Ivermectin is the drug that is currently used for on-
chocerciasis control through mass administration in en-
demic areas. It is known that a single standard dose
(150 μg/kg body weight) of ivermectin can result in 98–
99% reduction in skin microfilariae (Mf) within one
month of treatment [6].. Repopulation of skin by micro-
filariae occurs slowly, starting 3 months after treatment,
and by 6 and 12months after a single ivermectin dose,
the Mf load is expected to have recovered to approxi-
mately 10 and 20% of pre-treatment levels, respectively
[6]. A suboptimal response by parasites to ivermectin
will lead to a slow rate of Mf reduction as well as a faster
rate of Mf repopulation after treatment with a standard
dose of ivermectin. Faster rates of skin repopulation
have been reported in areas where parasites have experi-
enced long term exposure to ivermectin (over 12 rounds
of ivermectin mass drug administration (IVM-MDA)
when compared to areas naïve to treatment [7, 8]. In
contrast to previous studies where individuals from
naïve endemic areas were compared to those from areas
with long term exposure [7–9], participants in this study
were recruited from two areas with contrasting histories
of IVM-MDA to determine the effects of exposure to
one or two decades of treatment on parasite susceptibil-
ity to drug. Ivermectin therapeutic coverage between
2010 and 2014 was at least 75% (75–80%) in both
community directed treatment with ivermectin (CDTI)
project areas in Centre 1 and Littoral 2 [10] and
remained above 80% during the 2015, 2016 and 2017
treatment periods.
Microscopic detection and identification of Mf, based
on morphological characteristics [11, 12] in skin snips
remains the gold standard for the diagnosis of onchocer-
ciasis in humans [13, 14]. However, previous findings
have raised questions about the reliability of this method
due to the presence of Mf of other species which can
also reside in the skin. In one study, Mansonella strepto-
cerca Mf in skin snips using PCR techniques, raised
doubts about the specificity of microscope-based diagno-
sis of O. volvulus infection [15]. Similar concerns were
reported recently following the detection of Loa loa Mf
in skin snips in Cameroon [16]. Moreover, microscopy
may not be able to detect infection in patients with very
low microfilaridermia [11]. In addition, the insufficient
sensitivity of skin snip microscopy has been demon-
strated in a report from Uganda and Ethiopia where 84
of 853 samples that were declared negative by micros-
copy were positive using polymerase chain reaction
(PCR) and Melt-Curve Analysis (PCR-MCA) [12]. The
low sensitivity of microscopy can be more pronounced
when people are treated with a microfilaricide which will
further lower the Mf density [11, 12]. Conclusively, mi-
croscopy could be defined as an imperfect gold standard.
Thus, the suboptimal sensitivity of classical microscopy
inherently provides inaccurate information for modelers
and therefore, existing predictions (ONCHOSIM and
EPIONCHO) for the national programmes to evaluate
the progress towards elimination of transmission were
based mainly on microscopic examination and might be
insufficient and too optimistic [17]. Therefore, there is
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an urgent need to apply accurate, simple and affordable
diagnostic tools to detect low O. volvulus infection levels
in humans during monitoring and evaluation of clinical
trials as well as control and elimination programs.
Besides microscopy [11], immunological [18, 19] and
nucleic acid-based methods, specifically PCR [20, 21] and
LAMP [22, 23] have been used to diagnose O. volvulus in
skin. Although there have been advances in the develop-
ment of immunological methods involving detection of ei-
ther antibody or antigen [18, 19], cross-reactivity with
other filarial species has been reported [24]. The specificity
for O. volvulus requires the use of a probe [25]. PCR as-
says have been developed for microfilariae detection in
skin biopsies using different DNA targets including the
Onchocerca-specific tandemly repeated DNA sequence
family with a unit length of 150 base pairs (O-150) [12, 26,
27] and Ov Actin [28–30]. However, PCR-based methods
can be time consuming, require highly purified DNA and
require expensive equipment and material compared to
microscopy. Nevertheless, this technology was shown to
be more sensitive than microscopy [12, 21]. Alternatively,
loop-mediated isothermal amplification (LAMP) is a
simple molecular method which rapidly synthesizes large
amounts of DNA within 60min and which is less sensitive
to DNA impurities and has higher amplification efficiency
than PCR [22, 23, 31–34]. In addition, LAMP does not re-
quire any expensive equipment and thus it is easier to use
in low resource-settings [35–38]. LAMP assays targeting
O-150 and the mitochondrial cox1 gene have been estab-
lished for the diagnosis of onchocerciasis [22, 23, 36].
The purpose of this study was to decipher two com-
plementary objectives: (i) to assess the susceptibility of
O. volvulus Mf to IVM in two regions that have under-
gone IVM-MDA for different time periods, and (ii) to
document the repopulation of skin by the O. volvulus
Mf within six months following IVM treatment, while
comparing the performance of 3 independent diagnostic
techniques: microscopy, actin-qPCR and O-150 LAMP.
Method
Study area
This study was carried out in the Bafia (more than 20
rounds of annual IVM-MDA, with forest-savannah tran-
sitional ecosystem) and Melong (10 rounds of annual
Fig. 1 Overview of the study area including Bafia and Melong Health Districts and study communities. This map was created using ArcGIS
(ArcMap v10.5.1) software
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IVM-MDA, with forest bioecology) Health Districts
(HD) situated in the Centre and Littoral Regions of
Cameroon, respectively (Fig. 1a). These areas were
among the onchocerciasis foci that benefited from
APOC oriented CDTI program in Cameroon, but differ
in the number of annual rounds of MDA. Twenty-three
first-line (closest to the breeding sites) and second-line
villages (5–10 km away from breeding sites) grouped
into 14 communities were purposely selected for the
study. First and second line communities were selected
as their infection prevalence are usually higher due to
the fact that they are closer to the vector breeding sites,
hence higher biting rates and potentially higher infection
rate in the human population. Villages that were very
close to each other (< 2 km apart) were treated as be-
longing to the same community.
Bafia Health District
In this (HD), nine villages along the Mbam River,
grouped into six communities (Balamba 1, Balamba 2,
Biamo, Botatango/Boalondo, Lable/Nyamsong and
Ngomo/Biatsota) were purposely selected for the
study (Fig. 1b). The Bafia HD is in the Mbam and
Inoubou Division of the Centre Region of Cameroon.
It belongs to the Centre 1 CDTI project area and has
had over 20 rounds of annual CDTI but is still meso
endemic for onchocerciasis [39]. The altitude of this
forest savanna transition zone varies from 1100 to
1300 m above sea level and lies between coordinates
4°45′00″ north and 11°14′00″ east. The main activ-
ities of the inhabitants are agriculture (mainly cocoa
and cassava production) along the river beds, fishing
and sand mining, all of which expose them to re-
peated Simulium bites. The Mbam river offers an ex-
cellent breeding site for Simulium throughout the
year because of the presence of Mape dam that re-
leases water from its lake during the dry season to
regularize the course of the Sanaga river in view of
stabilizing the production of electrical energy at Edea.
Most of the first-line communities in the Bafia HD
are situated close to the main river.
Melong Health District
In this HD, fourteen first and second-line villages
along the Nkam River and its tributaries grouped into
eight communities (Mounko, Manjibo, Singa/Mbie/
Barembeng2/Longze, Ndoumbot/Ntangtom, Nkoniako-
niama/Nkonianke/Nkoniambot, Ndom-Bakem, Bare-
mbeng1 and Mpaka) were purposely selected for the
study (Fig. 1c). The Melong HD is in the Mungo Div-
ision of the Littoral Region of Cameroon and belongs
to the Littoral 2 CDTI project areas. It has received
10 rounds of annual IVM-MDA with a drastic drop
in disease prevalence (over 20% nodule prevalence in
adult males before CDTI [40] which could be trans-
lated to approximately over 40% Mf prevalence as re-
ported in areas naïve to ivermectin treatment [41], to
the observed 11.7% microfilaridemia among partici-
pants screened for this study). The district is located
in a forest ecosystem and the main activity of the in-
habitants is farming of cocoa, coffee and palm oil.
Villages in this HD are not too close to the main
Fig. 2 Overview of the study design
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river Nkam and the transmission is more ensured by
the tributaries of river Nkam which are affected nega-
tively by the reduction in water volume during the
dry season.
Study design
The study design is summarized in Fig. 2. The field ac-
tivities spanned a period of eight months (May 2016 to
January 2017) beginning with sensitization and
mobilization of the populations. All members in the se-
lected communities that met the eligibility criteria were
invited to take part in the screening at the time when
the research team arrived at each of them.
Convenience sampling was used to recruit eligible sub-
jects to be included in the follow up study, whereby, resi-
dents of selected communities were screened for
onchocerciasis at 12months after the last IVM-MDA. In-
dividuals aged 5 years and above who had lived in the
community for at least 5 years and consented/assented to
participate in the study were examined for the presence of
palpable nodules and Mf in the skin (O. volvulus) while
Mansonella perstans and Loa loa infections were deter-
mined microscopically using thick blood film (TBF). No
night blood for detection of Wuchereria bancrofti Mf was
performed since recently it has been shown that the para-
site is not endemic in this area of Cameroon [42]. Individ-
uals who were not microfilaridermic following skin snip
examination, underwent IVM-MDA using the routine
CDTI strategy. Consenting O. volvulus microfilaridermic
individuals who were negative for M. perstans and L. loa
were treated with IVM under direct observation (DOT) by
health personnel who were members of the research team.
All skin snip positive individuals who did not take treat-
ment under direct observation and those who did not sign
an informed consent for the follow-up study were ex-
cluded. The dosage of IVM was calculated according to
the individual’s height [43]. All persons that were not re-
cruited for this study were encouraged to take part in the
routine annual MDA.
Following DOT with ivermectin under the supervision
of a health worker who was a member of the research
team, skin snips were collected after 1 month (D30) and
examined for O. volvulus Mf. Susceptibility to IVM 1
month after treatment was determined using two ap-
proaches: (i) determining percent reduction of Mf by
comparing the geometric mean density of Mf per skin
snip (GMMfD/ss) at D30 to pre-treatment levels and (ii)
determining the proportion of microfilaridemia positiv-
ity. In addition, skin Mf was monitored at 1 month
(D30), 3 months (D90) and 6months (D180) using mi-
croscopy, actin-qPCR and O-150 LAMP techniques. By
identifying eligible participants using a less sensitive
method (microscopy) and monitoring the outcome of
IVM treatment at 30-, 90- and 180-days using
microscopy actin-qPCR and O-150 LAMP, this study de-
sign intended to circumvent the use of microscopy (an
imperfect gold standard) for comparison. The Bayesian
Latent Class model (described below) was used to com-
pute the performance characteristics of the three diag-
nostic tests.
Nodule palpation
Nodule palpation was carried out as described by Wanji
and colleagues [44]. Following their consent, participants
were partially undressed and examined using Rapid Epi-
demiological Assessment (REA) guidelines [45–47] with
emphasis being made to the bony prominences of the
iliac crest, torso, knees, arms, head,upper trochanter and
femur. The number of nodules found were recorded and
their positions noted on anatomical diagrams on the
participant recruitment forms.
Preparation and microscopy of thick blood film (TBF)
Day Blood (50 μL) was collected from 8 AM to 4 PM
with a non-heparinized microcapillary tube (soda lime
glass, Modulohm A/S Herlev, Denmark.) to identify Loa
loa or Mansonella perstans infections. The microcapil-
lary tube was centered on a clean slide then the blood
was smeared in a circular area of about 1.5 cm. The
smears were then air dried, packaged for transport back
to the base and finally stained with 10% Giemsa within
24 h. The stained smears were examined using a light
microscope (Brunel Microscopes Ltd., Chippenham,
United Kingdom) with 10× (or 40×) objective lens for
blood dwelling Mf. Any Mf present, were identified,
quantified and recorded.
Collection and microscopy of skin biopsies
Skin snipping was carried out as previously described
[44]. In summary, two bloodless skin biopsies were
taken, one from each iliac crest using a 2mm corneo-
scleral punch (CT 016 Eberhard’s 2218–15 C, Germany).
The snipped areas were dusted with Baneocin antiseptic
powder. The skin samples from each participant were
placed in two separate wells of a 96 well microtiter plate
containing 100 μL of saline. The plates were then sealed
with parafilm to prevent any spill-over or evaporation
and were incubated at room temperature for 24 h.
Emerged microfilariae were counted using a light micro-
scope at 10x magnification and each result was
expressed per skin snip [44, 48]. Then, residual skin bi-
opsies were transferred into 1.5 mL tubes (Eppendorf
AG, Hamburg, Germany) containing 80% ethanol
(GAPUMA UK Limited) and stored at − 20 °C for DNA
extraction and PCR and LAMP analyses.
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Genomic DNA extraction from skin biopsies
Skin biopsies were thawed and placed into 2 mL tubes
(Eppendorf AG) containing 160 μL of 1X Phosphate
Buffered Saline (SIGMA-ALDRICH, USA) and 18–20
(1.0–1.3 mm) glass beads (VWR International, Darm-
stadt, Germany) to be homogenized at 7000 rpm for 180
s using the MagNA Lyser Instrument (Roche Diagnos-
tics GmbH, Mannheim, Germany). Then, the QIAGEN
DNeasy® Blood & Tissue Kit (250) (Qiagen, Hilden,
Germany) was used to extract genomic DNA according
to the manufacturer’s instructions. Briefly, 180 μL of
ALT buffer and 20 μL of proteinase K were added into
the homogenate and incubated at 56 °C in a water bath
overnight. Following the overnight incubation, samples
were vortexed for 15 s before addition of 200 μL of AL
buffer and incubated for another 10 min at 56 °C. Then
200 μL of 96% ethanol (GAPUMA UK Limited) were
added and mixed with the sample before pipetting into a
DNeasy Mini spin column which was placed in a 2 mL
collection tube. After centrifugation at 8000 rpm for 60
s, the flow through and collection tubes were discarded
and the spin column was placed in a new 2mL collec-
tion tube. Then, two washing steps using 500 μl of
AW1and AW2 were performed before the DNA was
eluted by adding 200 μL of the AE elution buffer. Upon
10min incubation at room temperature the DNA was
collected into a 1.5 mL tube (Eppendorf AG) through
centrifugation for 60 s at 8000 rpm. Finally, the eluted
DNA was stored at − 20 °C until use for actin-qPCR and
LAMP assays.
O. volvulus-specific duplex real-time PCR
We carried out specific real-time PCR (OvwFtsZ/actin
duplex real-time PCR) to determine the presence of O.
volvulus and/or Wolbachia endobacteria infection in
skin biopsies. This PCR was performed using Qiagen’s
QuantiNova Probe PCR Kit (Qiagen, Hilden, Germany)
including Hotstar Taq, 10X buffer and 25 mM MgCl2.
Prior to the assay, DNA samples from the skin biopsies
were tested for PCR inhibitory factors using Mouse IFN-
γ real-time PCR as described previously [28], but no in-
hibition was detected (S1 Fig pdf). The actin-2 gene
(GenBank: M84916) for the O. volvulus nematode and
wFtsZ gene (GenBank: AJ276501) for Wolbachia endo-
bacteria were used. The PCR was conducted using 2 μL
DNA in 10 μL volume in a RotorGene 6000 (Qiagen) with
the following reaction mixture: 1X QuantiNova Probe
PCR Master Mix (Qiagen), 0.4 μM OvwFtsZ Fw (5′-
AGGAATGGGTGGTGGTACTG-3′), 0.4 μM OvwFtsZ
Rev. (5′-CTTTAACCGCAGCTCTTGCT-3′), 0.4 μM
OvActin Fw (5′-GTGCTACGTTGCTTTGGACT-3′),
0.4 μM OvActin Rev. (5′-GTAATCACTTGGCCAT
CAGG-3′), 0.025 μM OvwFtsZ TaqMan Probe (Fam-
CCTTGCCGCTTTCGCAATCAC-3′), 0.05 μM OvActin
TaqMan Probe (JOE-AACAGGAAATGGCAACTG
CTGC-3′). The cycling conditions were 95 °C for 2min
and 45 cycles of 95 °C 5 s and 58 °C 30 s. Fluorescence was
acquired on the FAM (Green) and JOE (Yellow) channels
at the end of the hybridization step. Plasmids (E6 copies/
μL) containing the respective sequences were used as PCR
positive controls in every run. Signals were analyzed using
Rotor-Gene Software version 2.3.1 with threshold set to
0.02 and an outlier removal of 15%. A positive signal
(maximum Ct value of 33) in the OvActin PCR was con-
sidered positive for O. volvulus infection. We standardized
the experiment by running a 1:10 serial dilution of the
plasmid DNA. The real-time PCR had a limit of detection
of 10 copies/μL, meaning that 2/3 replicates had the same
Ct (S2 Fig pdf). For this study, only the OvActin results
were considered in determining O. volvulus Mf in the skin
snips.
O. volvulus-specific colorimetric LAMP assay
To detect O. volvulus DNA from skin biopsies, we per-
formed the colorimetric O-150 LAMP assay as previ-
ously described [22] with some modifications. The
primer sets consisted of the following sequences; F3:
Forward outer primer (5′-TGGAAATTCACCAAAATA
TGGT-3′), B3: Backward outer primer (5′-GGGTAC
GTACCTTCAAACTG-3′), FIP: Forward inner primer
(5′-TGATGACCTATGACCCTAATCTCAACGAATAT
TTTTCTTAGGACCCAAT-3′), and BIP: Backward
outer primer (5′-TGAAAATGCGTTTTTCGCCGGG
GTCCTAAGAAAAATATTCGACTA-3′). LAMP reac-
tions contained 1.6 μM each of primers FIP and BIP,
0.2 μM each of F3 and B3, in 1X WarmStart Colorimet-
ric LAMP Master Mix (New England Biolabs Inc., Ips-
wich, USA) with 2 μL of template DNA, or H20 for non-
template controls (NTCs) in a total volume of 25 μL. Re-
actions were incubated at the optimal temperature of
64 °C for 60 min in a GeneAmp®, PCR System 9700 (Ap-
plied Biosystems, Foster City, USA). Amplification re-
sulted in a color change from pink to yellow in positive
samples, while negative samples remained pink with no
ambiguity in color determination when read against a
white background (white A4 paper). Because of the
high sensitivity of LAMP, DNA contamination and
carry over of amplified products was prevented by
using filter tips at all times, cleaning all work surfaces
with 10% bleach solution before and after each ses-
sion of work, performing each step of the analyses in
separate work areas and minimizing manipulation of
the reaction tubes. The assay was optimized using
DNA from O. volvulus microfilariae as positive con-
trol and nuclease free water as negative control. DNA
samples from M. perstans and L. loa were also used
to confirm the specificity of the test.
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Data management and analyses
Data collected were recorded into a template developed
in Microsoft Excel 2013 and later exported to SPSS ver-
sion 20 (IBM SPSS Statistics 22; Armonk, NY) for statis-
tical analysis. All differences were considered statistically
significant at P-values < 0.05. Proportion of Mf positivity
was expressed as a percentage of the number examined
at different time points of the follow ups. Chi-square test
was used to check for significant differences in the posi-
tive rates between the screening techniques at different
screening time points.
A web-based application described by Lim et al. [49]
and based on Bayesian Latent Class Models (LCM) was
used to determine the accuracy (sensitivity, specificity,
positive predictive value (PPV) and negative predictive
value (NPV)) of the diagnostic tests using microscopy as
an imperfect gold standard with the help of a simplified
interface of three-tests in one-population model (Walter
and Irwig model) [49]. In brief, Bayesian LCMs estimate
accuracies of diagnostic tests based on the true disease
status of each patient. Bayesian LCMs do not assume
that any diagnostic test or combination of diagnostic
tests is perfect [50, 51]. Table S1 shows the data input
into the Web-based application template.
Results
Nodule prevalence
Nodule prevalence of 41.5% (161/388) and 28.4% (170/
599) were observed in the Bafia and Melong HDs,
respectively.
Identification of mf positive participants eligible for direct
IVM treatment and follow-up
In the Bafia HD (Table 1), a total of 388 participants
composed of 311 adults (≥20 years) and 77 children (5–
19 years) were recruited for screening by microscopy.
Most of the adults are farmers (236 participants). The
gender and age group distribution in each community
were determined (Table 1, S2 Table). Of 388 individuals
who provided skin biopsies (Table 1), 105 (27.1%) were
positive for skin Mf. The distribution of microfilaridemic
positivity within the study communities were statistically
significant (P = 0.001). The villages of Boalondo/Bota-
tango had the highest level of endemicity (45.3%). Of the
105 individuals positive for skin Mf, 73 were males and
32 were females. Males (31.9%) had significantly higher
infection rates (P = 0.018) than females (20.1%). A total
of 30.4% (95/312) of adults were positive for skin Mf
compared with 13.2% (10/76) of children and the differ-
ence between these 2 groups was statistically significant
(P = 0.007).
In the Melong HD (Table 2), the 599 participants
comprised 467 adults, who were mainly farmers, and
132 children. The gender and age group distribution in
each community were determined (S3 Table).
Following evaluation (Table 2), 70 (11.7%) participants
were found positive for skin Mf. The villages of Ndoum-
bot/Ntangtom in the Melong HD had the highest pro-
portion of infected persons (25.5%). Of the 70
individuals positive for skin Mf, 44 (15.5%) were males
and 26 (8.2%) were females, and this difference was sta-
tistically significant (P = 0.005). Overall, 11.8% (55/467)
of adults and 11.4% (15/132) of children were positive
for Mf. Thus, the Bafia HD had significantly higher skin
Mf proportions compared to the Melong HD (P = 0.002).
From the 987 persons screened in the Bafia and Mel-
ong HDs, 175 microfilaridemic individuals were identi-
fied as potential candidates for the follow-up study.
However, follow-up samples were only available from
those who voluntarily consented.
Table 1 Screened participants positive for O. volvulus Mf in the Bafia HD
Variables Study populations Number examined Number positive Percentage (%) P – value (x2 test)
Sex Male 229 73 31.9 0.018
Female 159 32 20.1
Total 388 105
Age- group Children (5–19 years) 76 10 13.2 0.007
Adults (≥20 years) 312 95 30.4
Total 388 105 27.1
Communities Balamba 1 28 7 25.0 0.001
Balamba 2 57 5 8.8
Biamo 68 23 33.8
Boalondo/Botatango 53 24 45.3
Lable/Nyamsong 88 12 13.6
Ngomo/Biatsota 94 34 36.2
Total 388 105 27.1
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In total 51 and 44 individuals could be recruited for
the follow up study from the Bafia and Melong HD, re-
spectively. The socio-demographic data from those indi-
viduals are shown in S4 and S5 Tables. Comparison
analyses were made only for eligible participants (51, 51
and 48 at 1-, 3- and 6-months post-treatment in the
Bafia HD as well as 29, 44 and 38 at 1, 3 and 6months
after treatment in the Melong HD) from whom samples
were collected at each of follow-up time points. A total
of 150 skin snip samples from Bafia HD and 111 skin
snip samples from Melong HD were collected for ana-
lysis (S6 table). None of the microfilaridemic participants
were co-infected with M. perstans or L. loa as deter-
mined by thick blood films.
Susceptibility of O. volvulus microfilariae to ivermectin in
two areas of contrasting MDA history following direct
observed IVM treatment
Ivermectin led to a rapid drop in the proportion of
microfilaridemic individuals after one month of treat-
ment in both study sites (Fig. 3a). The proportion of par-
ticipants detected with infection at the 1-month follow-
up was significantly higher in the Bafia HD (21.6%) com-
pared to the Melong HD (6.9%). The repopulation trend
showed an increase in proportions of microfilaridemic
individuals over time (D30 prevalence < D90 prevalence
< D180 prevalence) by all techniques. However, the re-
population rate was faster in Bafia than Melong HD,
presented by the larger surface area under the curves for
geometric mean Mf density (Fig. 3b) and Mf reduction
rate (Fig. 3c).
In detail, the pre-treatment geometric mean density
for the 51 individuals recruited for follow-up in Bafia
HD was 3.331 Mf/ss. At 1-month follow-up, the geomet-
ric mean Mf density per skin snip (GMMfD/ss) was
0.442 Mf/ss. When the 1-month GMMfD/ss was com-
pared to the pre-treatment level, we observed 13.3% of
the initial density (86.7% Mf reduction rate) in the geo-
metric mean skin Mf (Fig. 3c). IVM treatment elicited a
statistically significant difference in the geometric mean
density of skin microfilaridemia after 30 days (P < 0.001).
At day 90 post treatment, all 51 follow-up participants
were again examined and the GMMfD/ss at this time
point was 0.379 Mf/ss. When compared to the pre-
treatment level of 3.331 Mf/ss, we had 11.4% of the ini-
tial density left which resulted to 88.6% Mf reduction
rate. After six months, 48 participants were examined
for the fourth and last time of the study and the
GMMfD/ss was 1.353 Mf/ss. The Mf reduction rate at 6
months was 59.4% with a skin microfilaria repopulation
rate of 40.6%. The reduction in geometric mean density
of skin microfilaridemia after 6 months was still signifi-
cant (P = 0.01). The trend in geometric mean Mf reduc-
tion rate at different follow-up time points and
repopulation of skin Mf shows a sharp decrease (86.7%)
within 1 month of treatment, a further but slower de-
crease to 88.6% between one and three months and a
rapid repopulation rate of 40.6% between the third and
the sixth months after treatment (Fig. 3b).
In the Melong HD pre-treatment geometric mean
density for the 44 individuals recruited for follow-up was
2.318 Mf/ss. At 1-month follow-up, it decreased to 0.051
for the 29 participants examined giving a reduction rate
of 97.8% (Fig. 3c). Repopulation gradually sets in at the
3-month follow-up at a rate of 9.4%, but remained low
even after 6 months (15%). The trend in geometric mean
Table 2 Screened participants positive for O. volvulus Mf in the Melong HD
Variables Study populations Number examined Number positive Percentage (%) p – value (x2 test)
Gender Male 283 44 15.5 0.005
Female 316 26 8.2
Total 599 70 11.7
Age group Children (5–19 years) 132 15 11.4 0.896
Adults (≥20 years) ( 467 55 11.8
Total 599 70 11.7
Community Mounko 60 4 6.7 0.002
Manjibo 51 12 23.5
Singa/Mbie/Barembeng2/Longze 104 10 9.6
Ndoumbot/Ntangtom 55 14 25.5
Nkoniakoniama/Nkonianke/Nkoniambot 87 7 8.0
Ndom-Bakem 79 10 12.7
Barembeng1 101 8 7.9
Mpaka 62 5 8.1
Total 599 70 11.7
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Mf reduction rate at different follow-up time points and
repopulation of skin Mf (Fig. 3b) shows a sharp decrease
(97.8%) within 1 month of treatment, and a very slow re-
population rate from three to sixth months after treat-
ment (Fig. 3b and c).
Monitoring skin mf rates after IVM treatment using
microscopy, PCR and LAMP technologies
In the Bafia HD, 51 eligible individuals were present for
the follow-ups and a total of 150 skin snips were col-
lected (Table 3).
Proportion of microfilaridemia positivity detected by
microscopy were 21.6% (11/51) after one month, 23.5%
(12/51) after three months, and 45.8% (22/48) after six
months. There was a statistically significant difference
(P = 0.014) in the prevalence levels obtained at the differ-
ent times of screening.
For the real-time actin-qPCR, a sample was considered
positive when the actin signal (in duplicate) was above
the threshold level. A representative set of samples from
individuals are shown in S3 Fig. This method detected
microfilaridemia proportion positivity of 23.5% (12/51),
31.4% (16/51) and 54.2% (26/48) at 1-, 3- and 6-months
post treatment, respectively. There was a significant dif-
ference in the real-time actin-qPCR prevalence at the
different time points (P = 0.005).
A colorimetric O-150 LAMP assay with a simple visual
readout (S4 Fig) was also used to detect infection in
DNA extracted from skin snips. Prior to initiation of the
amplification reaction, samples were pink. After a 60
Fig. 3 Microfilaridemia clearance and repopulation dynamics at 30, 60 and 90 days post direct observed IVM treatment in the Bafia and Melong
HDs: a Proportion of microfilaridemia positivity. b Geometric mean microfilarial density per skin snip (GMMfD/ss). C) Percent reduction
in GMMfD/ss
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min incubation at 64 °C, samples turned yellow in the
presence of O. volvulus DNA (S4A Fig). Samples
remained pink in the absence of template, or if DNA
from M. perstans or L. loa was present (S4B Fig), con-
firming the specificity of the LAMP assay. Colorimetric
LAMP detected infection in 15/51 individuals (29.4%) at
1-month following chemotherapy, while 19/51 (37.3%)
and 31/48 (64.6%) were detected after 3- and 6-months,
respectively. A significant difference in the proportion of
skin microfilaridemia positivity was also observed be-
tween the follow-up time points when using LAMP to
detect infection (P = 0.001).
Despite the difference in targets for determining para-
site infection, in Bafia HD, microscopy, actin-qPCR and
LAMP showed the same trend post treatment, namely a
steady increase in the proportion of microfilaridermia
positivity 1-, 3- and 6-months post treatment (Fig. 4).
The molecular assays were found to be more sensitive
than microscopy, with highest levels of sensitivity ob-
tained using LAMP. At each time point, the results ob-
tained by comparing the different diagnostic methods
were consistent (Microscopy < actin-qPCR < LAMP)
though not always significantly different (Fig. 4).
Table 3 Microfilaridemia detection rates by microscopy, actin-qPCR and O-150 LAMP at day 30, 60 and 180 post IVM treatment in
Bafia HD
Time point after
treatment (days)
Number of consented
eligible participants
Number of
samples
collected
Proportion positive for
microscopy n(%)
Proportion positive for
real-time PCR n(%)
Proportion positive for
O-150 LAMP n(%)
D30 51 51 11 (21.6%) 12 (23.5%) 15 (29.4%)
D90 51 51 12 (23.5%) 16 (31.4%) 19 (37.3%)
D180 51 48 22 (45.8%) 26 (54.2%) 31 (64.6%)
Total 150 45 (30%) 54 (36.0%) 65 (43.3%)
Significance P = 0.014 P = 0.005 P = 0.001
n = number of cases detected by each method
Fig. 4 O. volvulus microfilaridermia positivity rate at different time points following IVM treatment in the Bafia health district using microscopy,
actin-qPCR and O-150 LAMP assays
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However, significant differences were seen when com-
paring two techniques (in pairs) at each time point (Fig.
4).
In the Melong HD, 44 eligible recruited individuals
were present for the follow-up study and a total of 111
skin snip samples (Table 4) were collected from them at
1 month (29), 3 months (44) and 6months (38) post dir-
ect observed treatment, respectively.
Microscopy detected proportions of Mf positivity of
6.9% (2/29) after one month, 20.5% (9/44) after three
months and 23.7% (9/38) after six months. There was no
significant difference in the positive proportions by mi-
croscopy at the different follow-up time points (P =
0.18), however the positivity increased with time from 1
to 6 months post treatment. Actin-qPCR detected 4/29
(13.8%), 7/44 (15.9%) and 9/38 (23.7%) at 1-, 3- and 6-
months post treatment, respectively. Colorimetric LAMP
detected infections in 7 of the 29 individuals (24.1%), 12/
44 (27.3%) and 16/38 (42.1%) after 1-, 3- and 6-months
post treatment, respectively. No significant difference
was observed in the positive proportions between the
follow-up times regardless of the methods (Fig. 5). How-
ever, after combining the samples collected at all points
of monitoring (111), using the Chi square test, a signifi-
cant difference (P = 0.02) was observed between the re-
sults from the three diagnostic methods. When
comparing the performance of the techniques in pairs
(e.g. Microscope vs actin-qPCR or LAMP vs actin-
qPCR) significant differences in detecting infection
where observed (Fig. 5). Here too, LAMP assay detected
the highest microfilaridemia proportions compared to
the other methods at each time point (Fig. 5).
An overview of the individual results of the three dif-
ferent methods and time points are shown in S6 table.
Performance characteristics of actin-qPCR and O-150
LAMP assay using microscopy as the imperfect gold
standard
The observed frequencies of various test result combina-
tions were determined and entered into the data input
template (S1 Table) of the Web-based application for
each follow-up time point (D30, D90 and D180). The 3x
positive Serial Number 1 (SN1) and 3x negative (SN8) have
the highest numbers showing that actin-qPCR and O-150
LAMP confirm microscopy values. In addition, only posi-
tive in LAMP assay have the third highest observed fre-
quency suggesting that the LAMP assay has a higher
sensitivity compared to microscopy and actin-qPCR.
Finally, there are no observed frequencies when the
LAMP assay is negative whereas microscopy and actin-
qPCR are positive (SN2), further confirming the high
sensitivity of LAMP.
The accuracy (sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV)) of
actin-qPCR and O-150 LAMP using microscopy as im-
perfect gold standard for skin biopsy samples collected
from Bafia and Melong HDs are summarized in Tables 5
and 6, respectively.
The sensitivity of O-150 LAMP was generally higher
than that of actin-qPCR in detecting O. volvulus infec-
tion following treatment with a microfilaricide (IVM) in
both study sites (Tables 5 and 6) at different time points.
Bafia HD recorded sensitivities of 99.4% for O-150
LAMP, 98.1% for actin-qPCR and 80.7% for microscopy
while Melong HD had 98.5% for LAMP assay, 78.3% for
actin-qPCR and 80.2% for microscopy. With the excep-
tion at 3 months follow up in Melong HD, molecular
methods had higher and comparable sensitivities. In
both study sites, microscopy and actin-qPCR techniques
showed very high and comparable specificity values (al-
ways > 94%) while O-150 LAMP is relatively lower at all
the follow-up time points (ranging between 75 and 92%).
With exception at 1-month follow-up in Bafia HD, the
actin-qPCR assay had the highest PPV of over 92% at
the different time points. The LAMP had relatively lower
PPV compared to actin-qPCR and microscopy. In terms
of negative predictive value, LAMP had the highest
values (ranging between 98.1–99.6%) while the NPV of
microscopy and actin-qPCR were relatively lower and
comparable.
Discussion
For a microfilaricidal compound to be used in the con-
trol of onchocerciasis, the skin microfilarial clearance
Table 4 Microfilaridemia detection rate by microscopy, actin-qPCR and O-150 LAMP at day 30, 60 and 180 post IVM treatment in
Melong HD
Time point after
treatment (days)
Number of consented
eligible participants
Number of
samples
collected
Proportion positive for
microscopy n(%)
Proportion positive for
real-time PCR n(%)
Proportion positive for
O-150 LAMP n(%)
D30 44 29 2 (6.9%) 4 (13.8%) 7 (24.1%)
D90 44 44 9 (20.5%) 7 (15.9%) 12 (27.3%)
D180 44 38 9 (23.7%) 9 (23.7%) 16 (42.1%)
Total 111 20 (18.0%) 20 (18.0%) 35 (31.5%)
Difference P = 0.180 P = 0.520 P = 0. 215
n = number of cases detected by each method
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Fig. 5 O. volvulus microfilaridemia positivity rate at different time points following IVM treatment in Melong HD using microscopy, actin-qPCR
and O-150 LAMP assay
Table 5 Performance characteristics of the three tests in Bafia HD. Summary of sensitivity, specificity, PPV and NPV for microscopy,
actin-qPCR and O-150 LAMP at different time points following direct observed treatment of microfilaridermic individuals with
ivermectin in Bafia health district
METHODS SENSITIVITY SPECIFICITY PPV NPV
D30
MICROSCOPY 89.6 (61.6–99.9) 99.3 (93.0–100) 97.6 (76.9–100) 96.9 (86.2–100)
REAL-TIME PCR 89.6 (64.5–99.6) 96.8 (87.5–99.9) 89.6 (62.2–99.7) 96.8 (87.2–99.9)
LAMP ASSAY 97.6 (78.7–100) 92.1 (80.6–98.8) 79.0 (53.2–97.1) 99.2 (91.9–100)
D90
MICROSCOPY 71.4 (45.8–91.8) 96.9 (88.0–99.8) 90.6 (67.0–99.5) 88.8 (74.8–97.3)
REAL-TIME PCR 97.5 (75.8–100) 97.0 (86.3–100) 93.2 (69.3–99.9) 98.9 (87.8–100)
LAMP ASSAY 97.5 (79.0–100) 88.7 (75.0–97.6) 78.6 (54.5–95.7) 98.8 (89.1–100)
D180
MICROSCOPY 80.6 (62.9–93.1) 94.8 (81.3–99.6) 94.9 (80.6–99.6) 80.8 (61.5–93.4)
REAL-TIME PCR 98.9 (87.3–100) 98.5 (84.6–100) 98.8 (86.4–100) 98.7 (83.4–100)
LAMP ASSAY 99.0 (90.1–100) 76.6 (56.3–91.6) 83.4 (66.9–94.3) 98.6 (85.2–100)
D30 + D90 + D180
MICROSCOPY 80.7 (68.4–90.2) 97.4 (93.1–99.5) 94.5 (85.1–98.9) 90.3 (83.1–95.2)
REAL-TIME PCR 98.1 (90.0–100) 97.6 (92.7–99.8) 95.7 (87.1–99.6) 99.0 (94.2–100)
LAMP ASSAY 99.4 (93.4–100) 87.1 (79.4–93.1) 80.7 (69.6–89.9) 99.6 (95.8–100)
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and repopulation after treatment must be monitored
with the most appropriate, easy to use and available
diagnostic tool. In this study, the susceptibility and re-
population of skin microfilariae of O. volvulus were
monitored within six months of direct observed treat-
ment with IVM in two areas with different bioecology
and histories of MDA but with similar therapeutic
coverage, using three diagnostic methods (microscopy,
actin-qPCR and O-150 LAMP). Microscopy which is the
diagnostic gold standard for the detection of infection in
skin snips (though less sensitive when Mf density is very
low) [11, 14], was used to identify study participants
(microfilaridermic individuals) that were monitored for
the outcome of direct observed treatment with ivermec-
tin within 6 months using three independent detection
tools (microscopy, actin-qPCR and O-150 LAMP). Be-
fore the direct observed treatment intervention (after 12
months of the previous routine annual MDA), it was ob-
served that, despite long term IVM-MDA in both study
sites, the proportion of infected individuals amongst
those screened was still high (27.1%; ranging between
8.8–45.3% among communities in Bafia HD, and 11.7%;
ranging between 7.9–25.5% among communities in Mel-
ong HD) and might indicate an apparent failure of MDA
especially in Bafia. To determine the Mf clearance rate
by ivermectin at 1-month post treatment of microfilari-
demic individuals, the microscopy detected 21.6% (but
with 84.6% reduction rate in geometric mean density of
skin Mf) and 6.9% (but with 97.8% reduction rate in geo-
metric mean density of skin Mf) in Bafia and Melong
Health Districts, respectively. The higher proportion of
positive participants at the 1-month follow-up (Fig. 3a)
supported by the lower Mf reduction rate (Fig. 3b and c)
could suggest the presence of suboptimal response to
IVM or higher re-infection rates in Bafia compared to
Melong Health District where we observed a lower pro-
portion of positive participants after treatment and the
Mf reduction rate was close to the expected 98–99%
postulated by Basanez and colleagues [6] within 1–2
months after a single IVM dose. The higher percentages
of Mf detected in Bafia at different time points (Fig. 3b)
also shows that the parasite population in the area with
over 20 years of annual MDA is less susceptible to IVM
than those in Melong with a shorter exposure period
(10 years). This finding corroborates previous documen-
tation of suboptimal response of O. volvulus Mf to IVM
in Cameroon and Ghana [7, 8]. Again, the skin Mf re-
population rate at the 6-month follow-up in Bafia (47,
5%) is much higher than the expected repopulation rate
of less than 20% of pre-treatment load for up to 10
months post treatment modelled for IVM in a naïve
population of parasites [52]. This is another strong indi-
cation that worms with suboptimal response to IVM
may be present in Bafia HD that have received over 20
rounds of IVM-MDA.
From the dynamics of detecting infection after treat-
ment, all three diagnostic techniques used to monitor
the outcome of intervention showed a steady and similar
increasing trend in the proportion of microfilaridemia
positive samples from D30 through D90 to D180 in both
Table 6 Performance characteristics of the three tests in Melong HD. Summary of sensitivity, specificity, PPV and NPV for
Microscopy, actin-qPCR and O-150 LAMP at different time points following direct observed treatment of microfilaridermic individuals
with ivermectin in Melong Health District
METHODS SENSITIVITY SPECIFICITY PPV NPV
D30
MICROSCOPY 45.4 (10.1–91.2) 99.1 (89.7–100) 89.6 (29.3–100) 91.1 (71.0–99.2)
REAL-TIME PCR 87.6 (32.2–100) 98.7 (87.1–100) 92.2 (36.2–100) 98.0 (78.3–100)
LAMP ASSAY 94.2 (52.0–100) 89.3 (71.5–99.7) 60.5 (18.4–99.3) 98.9 (87.4–100)
D90
MICROSCOPY 90.6 (48.3–100) 94.7 (82.3–100) 78.9 (35.2–99.9) 98.0 (82.0–100)
REAL-TIME PCR 38.0 (10.9–80.6) 99.4 (92.9–100) 93.1 (43.4–100) 87.8 (69.8–97.9)
LAMP ASSAY 92.1 (55.3–100) 89.8 (75.9–99.7) 66.1 (28.1–99.2) 98.1 (84.9–100)
D180
MICROSCOPY 88.9 (58.1–99.9) 96.1 (84.9–99.8) 87.5 (59.2–99.4) 96.5 (84.5–100)
REAL-TIME PCR 96.7 (69.9–100) 98.8 (89.2–100) 96.2 (66.7–100) 99.0 (89.4–100)
LAMP ASSAY 97.1 (74.0–100) 75.3 (58.7–88.5) 55.0 (30.6–78.2) 98.9 (87.7–100)
D30 + D90 + D180
MICROSCOPY 80.2 (57.2–95.0) 95.9 (89.4–99.2) 81.5 (56.6–96.4) 95.7 (87.9–99.0)
REAL-TIME PCR 78.3 (53.3–97.9) 99.7 (96.5–100) 98.2 (82.1–100) 95.4 (87.4–99.7)
LAMP ASSAY 98.5 (84.3–100) 84.7 (75.6–92.3) 58.7 (39.1–79.4) 99.6 (95.4–100)
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study sites (Figs. 4 and 5) despite their historical and
ecological differences. This indicates that, all three tech-
niques were able to follow skin Mf reappearance after
treatment, but only differ in their level of sensitivity as
the nucleic acid-based techniques detected more infec-
tions than microscopy and this is in agreement with
earlier reports [12, 22, 23, 26, 36, 51, 53, 54].
As shown on Figs. 4 and 5, as well as Tables 5 and 6,
the LAMP assay was the most sensitive of the three
techniques in the detection of microfilaria in all the skin
biopsies and at all monitoring time points in both study
sites. This therefore implies that in terms of sensitivity,
LAMP assay with its reported advantages over actin-
qPCR in terms of cost, robustness and simplicity [55–
59] could be the most appropriate diagnostic tool to de-
tect the presence of O volvulus infection in humans [22,
23, 36] as well as monitor the clearance and reappear-
ance of skin Mf following treatment with a microfilarici-
dal compound as observed in this study. However, we
also observed that the specificity of LAMP is lower than
the actin-qPCR and a very high specificity (≥99%) of a
diagnostic technique is usually required for programme
evaluation. As previously reported [12, 60], our results
(Tables 5 and 6) also confirm the poor sensitivity of mi-
croscopy when Mf density is very low as it detected the
fewest number of infections among the three techniques
used for monitoring. It was also seen that, the sensitivity
of microscopy in the Melong HD after one month of
treatment was very low (45.4%) when compared to the
89.6% in the Bafia HD. These observations are in line
with the reduction rates in geometric mean densities of
skin Mf in both study sites (97.8 and 84.6% respectively).
This could be due to the fact that the drug effect on the
parasite population in Melong is more effective than on
the parasite population in Bafia HD. Hence, treatment
will lead to very low microfilaridermia in the Melong
HD which will further affect the poor sensitivity of mi-
croscopy as reported earlier [11]. Surprisingly, we ob-
served a few samples (2 in Bafia HD and 3 in Melong
HD; S1 Table, SN5) that were positive for microscopy
but negative for both nucleic acid-based tools and this
could have compromised their specificity. This observa-
tion could be due to the fact that, this study used re-
sidual skin snip biopsies, which are biopsies after
migration of the Mf outside of the tissue during the 24 h
incubation. Thus, no O. volvulus DNA could be ex-
tracted from those skin biopsies. Alternatively, the
microscopically assessed Mf could come from another
filarial species (e.g. Mansonella spp or L. loa) as demon-
strated in other studies [15, 16]. In addition to the high
sensitivity, the specificity of LAMP assay is also high
(ranging between 75 and 92%), though relatively lower
than that of actin-qPCR and microscopy. All non-
template control tubes as well as those with DNA from
other filarial species (M. perstans, L. loa) also confirmed
the assay’s species-specificity as they always remained
negative. The comparatively lower specificity of LAMP
in this study, could have been due to its ability to detect-
ing more infections than the imperfect gold standard.
For any assay to be considered in the monitoring of
transmission in elimination programmes, specificity
should be high (> 99%). For the fact that O-150 can be
amplified from multiple species of Onchocerca, and the
use of primers alone will not be definitive for detecting
O. volvulus in the vectors, the O-150 LAMP in this study
can only be used to detect Onchocerca infection in the
vectors without trying to differentiate the species.
Conclusion
We identified microfilaridermic individuals from two
health districts with different IVM-MDA histories and
levels of endemicity, treated them with a microfilaricide
(IVM) then followed their microfilaridemia dynamics at
different time points over a period of 6 months using
three diagnostic tools. The trends in microfilaridemia
clearance and repopulation after treatment with IVM
were established with parasites in Bafia HD that have
been exposed to IVM for over 20 years presenting sub-
optimal response characters (lower than expected clear-
ance and faster than expected repopulation rates) to
IVM when compared to those from the Melong HD
with just 10 years of exposure to the drug. The results
also support the already known higher sensitivity of
actin-qPCR over microscopy in detecting O. volvulus
skin Mf at all monitoring time points. The sensitivity of
the two nucleic acid-based techniques were comparable
even though O-150 LAMP detected the highest number
of infections at all monitoring time points. However, mi-
croscopy and actin-qPCR displayed better and compar-
able specificity than the O-150 LAMP assay. The high
sensitivity of O-150 LAMP added to its robustness, sim-
plicity, and relative cost effectiveness suggest that this
diagnostic method should be given consideration as one
of the reference diagnostic tools for monitoring Mf
clearance/reappearance in clinical trials and control/
elimination programs of onchocerciasis especially in
areas with limited resources if the specificity is improved
to or above 99%.
Limitations
The nucleic acid-based techniques were only used as a
qualitative method to detect the presence or absence of
parasite, not to quantify. Hence, they can be best appre-
ciated (especially the LAMP assay) in monitoring infec-
tion in foci that are nearing elimination criteria and
clinical trials that aim at eliminating all parasites after a
given period of treatment. In addition, the different tech-
niques had different targets for detection of infection.
Abong et al. BMC Infectious Diseases          (2020) 20:726 Page 14 of 17
Whole microfilariae for microscopy, and different DNA
targets for the molecular methods (real-time Ov-actin
PCR and O-150 LAMP), which makes the direct com-
parison of microscopy to real-time PCR and LAMP in
regards to sensitivity and specificity difficult to assess.
Also, gene copy numbers for O-150 are several logs
higher than actin causing a critical difference between
the actin-qPCR and the O-150 LAMP.
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three-tests in one-population model (Walter and Irwig model) in Bafia
and Melong Health Districts.
Additional file 6 S2 Table. Socio-demographic characteristics and dis-
tribution of participants screened by microscopy in the Bafia Health
District.
Additional file 7 S3 Table. Socio-demographic characteristics and dis-
tribution of participants screened by microscopy in the Melong health
district.
Additional file 8 S4 Table. Socio-demographic characteristics and dis-
tribution of participants that volunteered for the follow up study in the
Bafia health district.
Additional file 9 S5 Table. Socio-demographic characteristics and dis-
tribution of participants that volunteered for the follow up study in the
Melong health district.
Additional file 10 S6 Table. Table showing Mf. count, Ct values for
real-time PCR and time to LAMP for all samples investigated.
Additional file 11 S1 File. Diagnostic test results in Bafia Health District.
Additional file 12 S2 File. Diagnostic test results in Melong Health
District.
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